BioSpace News Archive

Code Ocean, today announced a collaboration that will power AI-driven computational research for oncology-focused drug discovery with Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development.

Inhibikase Therapeutics, Inc. today announced that Dr. Milton Werner , Ph.D., President & Chief Executive Officer of Inhibikase, will participate in the Michael J. Fox Foundation Alpha-Synuclein Summit being held virtually from November 3-4, 2021.

EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced the publication of a case report demonstrating the WiSE™ CRT System’s ability to successfully deliver leadless Left Bundle Branch Area Pacing (LBBAP).

Fulgent Genetics, Inc. today announced that it has launched an antibody test for COVID-19 which will specifically target neutralizing antibodies.

Apollo Endosurgery, Inc. today announced that the Company is scheduled to release its financial results for the third quarter ended September 30, 2021 on Monday, November 1, 2021 after the market closes.

Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, including type 2 diabetes, announced the publication of an innovative new model of metabolism, the Metabolic Balance Model.

ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it received Taiwan Central Institutional Review Board (CIRB) approval to begin a Phase II Part 2 study of its ABV-1505 Attention-Deficit Hyperactivity Disorder (ADHD) drug at five prestigious medical centers in Taiwan.

Novavax, Inc. (Nasdaq: NVAX), today announced the completion of its rolling regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine candidate.

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its third quarter 2021 financial results on Wednesday, November 10, 2021

IAVI announced today the award of up to US$126 million from the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services to develop two recombinant vesicular stomatitis virus (rVSV)-vectored filovirus vaccine candidates.